Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P13686

UPID:
PPA5_HUMAN

ALTERNATIVE NAMES:
Tartrate-resistant acid ATPase; Type 5 acid phosphatase

ALTERNATIVE UPACC:
P13686; A8K3V2; Q2TAB1; Q6IAS6; Q9UCJ5; Q9UCJ6; Q9UCJ7

BACKGROUND:
The protein Tartrate-resistant acid phosphatase type 5, with alternative names such as Tartrate-resistant acid ATPase and Type 5 acid phosphatase, is involved in the dephosphorylation of osteopontin. Its elevated expression in diseases like Gaucher and Hodgkin diseases underscores its pathological significance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Tartrate-resistant acid phosphatase type 5 could open doors to potential therapeutic strategies, especially considering its involvement in Spondyloenchondrodysplasia with immune dysregulation. This protein's function in autoimmune and bone diseases presents a promising avenue for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.